证券代码：688656 证券简称：浩欧博 公告编号：2025-059 江苏浩欧博生物医药股份有限公司 关于自愿披露签订合作框架协议暨风险提示公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、合作协议签订情况 1 江苏浩欧博生物医药股份有限公司（以下简称"公司"）与罗氏诊断产品（上 海）有限公司（以下简称"罗氏诊断"）签署《合作框架协议》（以下简称"本 协议"），双方就化学发光自身抗体检测产品领域开展合作。 本次签署的《合作框架协议》是以双方合作意向为原则的框架性陈述，不构成 强制的法律约束，亦不构成协议双方相互追究违约责任的依据。具体合作项目 需另行签署合作协议，双方的合作能否正常实施推进存在一定的不确定性。 本次签订的《合作框架协议》不涉及具体金额和项目合作的权利义务，具体的 交易细节需要双方在后期签署的正式合同或协议中另行约定，预计不会对公司 本年度的业绩及经营成果产生重大影响。 本协议履行实施过程中可能存在受宏观经济形势、行业政策及市场环境变化等 因素影响，可能存在履行效果不达预期或者合作终止 ...

Core Viewpoint - The company Haobo (688656) has signed a framework cooperation agreement with Roche Diagnostics (Shanghai) Co., Ltd. to collaborate in the field of chemiluminescent self-antibody testing products [1] Group 1 - The agreement serves as a foundational and guiding document for mutual cooperation projects between the two companies [1]

Core Viewpoint - The company has signed a cooperation framework agreement with Roche Diagnostics Products (Shanghai) Co., Ltd. to collaborate in the field of chemiluminescent self-antibody testing products. The agreement is non-binding and specific projects will require separate agreements [1] Group 1 - The cooperation period is set for 5 years, but the implementation of the cooperation may face uncertainties [1] - The agreement is a framework statement and does not have legal binding force [1] - The expected impact on the company's performance and operating results for the current year is not significant [1]

Core Viewpoint - The signing of the cooperation framework agreement between the company and Roche Diagnostics is a strategic move to enhance brand recognition and expand market share in the diagnostic reagent field [1] Group 1: Cooperation Agreement - The cooperation framework agreement is a non-binding statement of intent between the company and Roche Diagnostics [1] - The agreement does not impose legal obligations or grounds for liability for breach of contract [1] Group 2: Strategic Importance - The signing of the agreement is an important step in implementing the company's long-term development strategy [1] - Collaboration with Roche Diagnostics is expected to positively impact the company's development by enhancing brand recognition in the local market [1] Group 3: Market Expansion - The partnership aims to further expand the company's market share in the diagnostic reagent sector [1] - The collaboration will facilitate mutual learning and communication, leading to improved product quality and services for customers [1]

Group 1 - The core point of the news is that Jiangsu Haobo Bio-Pharmaceutical Co., Ltd. experienced a stock price increase of 5.59%, reaching 163.99 CNY per share, with a total market capitalization of 10.41 billion CNY as of October 20 [1] - The company, established on June 8, 2009, and listed on January 13, 2021, specializes in the research, production, and sales of in vitro diagnostic reagents [1] - The revenue composition of the company includes 89.46% from reagent sales, 5.86% from other sales, 3.84% from instrument sales, and 0.85% from leasing sales [1] Group 2 - From the perspective of fund holdings, one fund under China Merchants Fund has a significant position in Haobo Bio, with the China Merchants Growth Pioneer Stock A (014589) holding 11,300 shares, unchanged from the previous period, accounting for 4.54% of the fund's net value [2] - The fund has a total size of 29.46 million CNY and has achieved a year-to-date return of 32.34%, ranking 1195 out of 4218 in its category [2] - The fund manager, Mei Mei, has been in position for 270 days, with the best return during this period being 38.04% and the worst being -0.97% [2]

Group 1 - The core viewpoint of the news is that Jiangsu Haobio Pharmaceutical Co., Ltd. has seen a stock price increase of 5.34%, reaching 162.43 CNY per share, with a total market capitalization of 10.311 billion CNY [1] - The company, established on June 8, 2009, specializes in the research, production, and sales of in vitro diagnostic reagents, with reagent sales accounting for 89.46% of its main business revenue [1] - Other revenue sources include sales from other products at 5.86%, instrument sales at 3.84%, and rental sales at 0.85% [1] Group 2 - From the perspective of fund holdings, one fund under Shenwan Hongyuan has Haobio as a significant investment, holding 56,100 shares, which constitutes 5.74% of the fund's net value [2] - The fund, Shenwan Hongyuan Medical Pioneer Stock A, has a current scale of 120 million CNY and has experienced a loss of 2.93% this year, ranking 4172 out of 4220 in its category [2] - The fund manager, Yao Hongfu, has been in position for 3 years and 75 days, with the best and worst fund returns during his tenure being -30.26% and -31.14%, respectively [2]

Group 1 - The core point of the announcement is the resolution of the third extraordinary general meeting of shareholders of Jiangsu Haooubo Biopharmaceutical Co., Ltd. held on September 25, 2025, which included the approval of key proposals [1][4]. - The meeting was legally convened and conducted, with all procedures in compliance with the Company Law and the company's articles of association [2][5]. - All directors, supervisors, and the board secretary attended the meeting, confirming full participation from the company's leadership [3]. Group 2 - Two main proposals were approved during the meeting: the adjustment of the 2025 annual director remuneration and the purchase of liability insurance for directors, supervisors, and senior management [4]. - The voting process was conducted through a combination of on-site and online voting, ensuring that the resolutions were passed with more than half of the valid voting rights represented [5]. - The meeting was witnessed by legal representatives from Guohao Law Firm (Shanghai), who confirmed the legality and validity of the meeting's procedures and voting results [5].

证券代码：688656 证券简称：浩欧博 公告编号：2025-058 江苏浩欧博生物医药股份有限公司 2025年第三次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 9 月 25 日 （二） 股东大会召开的地点：公司会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 34 | | --- | --- | | 普通股股东人数 | 34 | | 2、出席会议的股东所持有的表决权数量 | 42,978,602 | | 普通股股东所持有表决权数量 | 42,978,602 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 68.5700 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 68.5700 | （四） 表决方式是否符合《公司法》及公司章程 ...

国浩律师（上海）事务所 法律意见书 国浩律师（上海）事务所 关于江苏浩欧博生物医药股份有限公司 2025 年第三次临时股东大会的法律意见书 致：江苏浩欧博生物医药股份有限公司 江苏浩欧博生物医药股份有限公司（以下简称"公司"）2025 年第三次临时 股东大会定于 2025 年 9 月 25 日召开，国浩律师（上海）事务所（以下简称"本 所"）接受公司的委托，指派陈晓纯律师、李嘉言律师（以下简称"本所律师"） 对本次股东大会进行见证，并依据《中华人民共和国公司法》（以下简称"《公司 法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、中国证券监督管 理委员会发布的《上市公司股东会规则》及其他现行有效的法律、法规及规范性 文件规定及《江苏浩欧博生物医药股份有限公司章程》（以下简称"《公司章程》"） 出具本法律意见书。 本所律师按照中华人民共和国（以下简称"中国"，仅为本法律意见书之目的， 不包括香港特别行政区、澳门特别行政区和台湾地区）现行法律、法规的规定， 列席了本次股东大会，审查了公司提供的有关本次股东大会各项议程及相关文件， 对本次股东大会的召集、召开程序是否合法及是否符合《公司章程》规定、出席 ...

Core Viewpoint - The company has signed an exclusive strategic cooperation agreement with Inmunotek S.L. to introduce and sell the Oraltek® series of desensitization drugs in the Chinese market, addressing the needs of allergy patients and enhancing the development of the allergy diagnosis and treatment industry [1] Group 1: Strategic Cooperation - The company will exclusively introduce Inmunotek's Oraltek® series of desensitization drugs to the Chinese market [1] - This partnership aims to implement the company's new business in the domestic desensitization drug sector [1] Group 2: Clinical Trials and Regulatory Approvals - The company's wholly-owned subsidiary, Shanghai Haobio Pharmaceutical Co., Ltd., has successfully completed the first batch of subject enrollment for the Phase III clinical trial of the desensitization drug MM09 sublingual spray [1] - Three products related to cat hair, dog hair, and house dust mites have received the "clinical urgently needed imported drug approval" under the "Guangdong-Hong Kong-Macao Greater Bay Area" policy [1]